Our results suggest adenylate cyclase as a new potential target for treating HLRCC patients, while the specific mechanism which renders it essential for the survival of FH-deficient cells remains an open question. The gene discussed is FH; the disease is hereditary leiomyomatosis and renal cell cancer.